Literature DB >> 20180931

Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa.

Matthew P Fox1, Alana Brennan, Mhairi Maskew, Patrick MacPhail, Ian Sanne.   

Abstract

OBJECTIVE: To estimate the rates of mortality in patients lost to follow-up (LTFU) from a large urban public sector HIV clinic in South Africa.
METHODS: We compared vital status using the clinic's database to vital status verified against the Vital Registration system at the South African Department of Home Affairs. We compared rates of mortality before and after updating mortality data. Predictors of mortality were estimated using Kaplan-Meier curves and proportional hazard regression.
RESULTS: Of the 7097 total patients who initiated highly active antiretroviral therapy at Themba Lethu Clinic by October 1st, 2008 and had an ID number, 6205 were included. 2453 patients (21%) were LTFU, of whom 1037 (42.3%) could be included in the analysis. After matching to the vital registration system, mortality more than doubled from 4.2% (258/6205) to 10.9% (676/6205). Overall 37% of those LTFU died by life-table analysis the probability of survival amongst those LTFU was 69% (95% CI: 66-72%), 64% (95% CI: 61-67%) and 59% (95% CI: 55-62%) by years 1, 2 and 3 since being lost, respectively. Those at highest risk of death after being lost were patients with a history of tuberculosis, CD4 count < 100 cells/microl, BMI < 17.5, haemoglobin < 10 and on <6 months of treatment.
CONCLUSION: Mortality was substantially underestimated among patients lost from a South African HIV treatment programme despite limited active tracing. Linking to vital registration systems can provide more accurate assessments of programme effectiveness and target lost patients most at risk for mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180931      PMCID: PMC2951133          DOI: 10.1111/j.1365-3156.2010.02473.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  17 in total

1.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

Authors:  Dilys Morgan; Cedric Mahe; Billy Mayanja; J Martin Okongo; Rosemary Lubega; James A G Whitworth
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

2.  Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world?

Authors:  Stephen D Lawn; Landon Myer; Robin Wood
Journal:  Clin Infect Dis       Date:  2005-12-01       Impact factor: 9.079

3.  Mortality and causes of death in South Africa, 1997-2003: findings from death notifications.

Authors:  Sarah Dougan
Journal:  Euro Surveill       Date:  2005-03-31

4.  When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

Authors:  Motasim Badri; Susan Cleary; Gary Maartens; Jennifer Pitt; Linda-Gail Bekker; Catherine Orrell; Robin Wood
Journal:  Antivir Ther       Date:  2006

5.  Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group.

Authors:  A J Mocroft; J D Lundgren; A d'Armino Monforte; B Ledergerber; S E Barton; S Vella; C Katlama; J Gerstoft; C Pedersen; A N Phillips
Journal:  Int J Epidemiol       Date:  1997-04       Impact factor: 7.196

6.  Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults.

Authors:  Christian Laurent; Ndeye Fatou Ngom Gueye; Cheikh Tidiane Ndour; Pape Mandoumbé Gueye; Martin Diouf; Ndella Diakhaté; Ndeye Coumba Touré Kane; Isabelle Lanièce; Adama Ndir; Laurence Vergne; Ibrahima Ndoye; Souleymane Mboup; Pape Salif Sow; Eric Delaporte
Journal:  J Acquir Immune Defic Syndr       Date:  2005-01-01       Impact factor: 3.731

7.  Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.

Authors:  Louise C Ivers; David Kendrick; Karen Doucette
Journal:  Clin Infect Dis       Date:  2005-05-27       Impact factor: 9.079

8.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.

Authors:  David Coetzee; Katherine Hildebrand; Andrew Boulle; Gary Maartens; Francoise Louis; Veliswa Labatala; Hermann Reuter; Nonthutuzelo Ntwana; Eric Goemaere
Journal:  AIDS       Date:  2004-04-09       Impact factor: 4.177

9.  Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.

Authors:  Martin W G Brinkhof; Mar Pujades-Rodriguez; Matthias Egger
Journal:  PLoS One       Date:  2009-06-04       Impact factor: 3.240

Review 10.  Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review.

Authors:  Sydney Rosen; Matthew P Fox; Christopher J Gill
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

View more
  86 in total

1.  Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa.

Authors:  Denise Evans; Mhairi Maskew; Ian Sanne
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-03

2.  Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa.

Authors:  Mhairi Maskew; Alana T Brennan; A Patrick MacPhail; Ian M Sanne; Matthew P Fox
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2011-09-27

3.  Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa.

Authors:  Kate Shearer; Mhairi Maskew; Toyin Ajayi; Rebecca Berhanu; Pappie Majuba; Ian Sanne; Matthew P Fox
Journal:  Int J Infect Dis       Date:  2014-03-25       Impact factor: 3.623

4.  Impact of Unplanned Care Interruption on CD4 Response Early After ART Initiation in a Nigerian Cohort.

Authors:  Aimalohi A Ahonkhai; Juliet Adeola; Bolanle Banigbe; Ifeyinwa Onwuatuelo; Abdulkabir B Adegoke; Ingrid V Bassett; Elena Losina; Kenneth A Freedberg; Prosper Okonkwo; Susan Regan
Journal:  J Int Assoc Provid AIDS Care       Date:  2016-10-10

5.  Outcomes of antiretroviral treatment programs in rural Southern Africa.

Authors:  Gilles Wandeler; Olivia Keiser; Karolin Pfeiffer; Sabrina Pestilli; Christiane Fritz; Niklaus D Labhardt; Franzisco Mbofana; Robert Mudyiradima; Jan Emmel; Matthias Egger; Jochen Ehmer
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

6.  Prevalent tuberculosis and mortality among HAART initiators.

Authors:  Daniel Westreich; Matthew P Fox; Annelies Van Rie; Mhairi Maskew
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

7.  Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa.

Authors:  Matthias Egger; Didier K Ekouevi; Carolyn Williams; Rita Elias Lyamuya; Henri Mukumbi; Paula Braitstein; Tyler Hartwell; Claire Graber; Benjamin H Chi; Andrew Boulle; François Dabis; Kara Wools-Kaloustian
Journal:  Int J Epidemiol       Date:  2011-05-18       Impact factor: 7.196

8.  Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.

Authors:  Alana T Brennan; Kate Shearer; Mhairi Maskew; Lawrence Long; Ian Sanne; Matthew P Fox
Journal:  Trop Med Int Health       Date:  2014-03-03       Impact factor: 2.622

9.  Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults.

Authors:  Mhairi Maskew; A Patrick MacPhail; Denise Whitby; Matthias Egger; Matthew P Fox
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

Review 10.  Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review.

Authors:  Matthew P Fox; Sydney Rosen
Journal:  Trop Med Int Health       Date:  2010-06       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.